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Abstract
Mutations in the fused in sarcoma/translated in liposarcoma gene (FUS/TLS, FUS) have been identified in sporadic and
familial forms of amyotrophic lateral sclerosis (ALS). FUS is an RNA-binding protein that is normally localized in the nucleus,
but is mislocalized to the cytoplasm in ALS, and comprises cytoplasmic inclusions in ALS-affected areas. However, it is still
unknown whether the neurodegeneration that occurs in ALS is caused by the loss of FUS nuclear function, or by the gain of
toxic function due to cytoplasmic FUS aggregation. Cabeza (Caz) is a Drosophila orthologue of human FUS. Here, we
generated Drosophila models with Caz knockdown, and investigated their phenotypes. In wild-type Drosophila, Caz was
strongly expressed in the central nervous system of larvae and adults. Caz did not colocalize with a presynaptic marker,
suggesting that Caz physiologically functions in neuronal cell bodies and/or their axons. Fly models with neuron-specific
Caz knockdown exhibited reduced climbing ability in adulthood and anatomical defects in presynaptic terminals of
motoneurons in third instar larvae. Our results demonstrated that decreased expression of Drosophila Caz is sufficient to
cause degeneration of motoneurons and locomotive disability in the absence of abnormal cytoplasmic Caz aggregates,
suggesting that the pathogenic mechanism underlying FUS-related ALS should be ascribed more to the loss of
physiological FUS functions in the nucleus than to the toxicity of cytoplasmic FUS aggregates. Since the Caz-knockdown
Drosophila model we presented recapitulates key features of human ALS, it would be a suitable animal model for the
screening of genes and chemicals that might modify the pathogenic processes that lead to the degeneration of
motoneurons in ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating neurode-
generative disease that is characterized by degeneration of motor
neurons, which leads to progressive muscle weakness and
eventually fatal paralysis, typically within 1 to 5 years after disease
onset [1]. Frontotemporal lobar degeneration (FTLD) is a
clinically diverse dementia syndrome, with phenotypes that
include behavioral changes, semantic dementia and progressive
non-fluent aphasia [2]. Although these two diseases are clinically
distinct and affect different parts of the central nervous system, it
has been long thought that these two diseases are related since
ALS patients often develop cognitive deficits with frontotemporal
features and FTLD patients can present symptoms of motor
neuron disease [3,4]. This hypothesis, which was derived from
clinical observations, has been biochemically confirmed by
identification of the 43 kDa TAR-DNA-binding protein (TDP-
43) as the major aggregating protein in subtypes of both ALS and
FTLD (ALS-TDP and FTLD-TDP, respectively) [5,6]. Moreover,
over 30 different mutations in the TDP-43 gene (TARDBP) have
been identified in various sporadic and familial ALS patients [7–
12], and subsequently TDP-43 mutations were reported in various
FTLD-TDP cases [13,14]. Shortly after the identification of
mutations in TDP-43 in ALS cases, mutations in another gene
encoding an RNA-binding protein, FUS (fused in sarcoma; also
known as TLS, translocated in liposarcoma), were identified in
cases with familial ALS (ALS-FUS) [15,16]. Both dominantly and
recessively inherited FUS mutations have been reported in familial
ALS [15], and FUS mutations may be more common than
TARDBP mutations in familial ALS [17]. Additional mutations in
FUS have recently been identified in sporadic ALS cases and in a
subset of FTLD cases (FTLD-FUS) [18,19]. FUS is normally a
nuclear protein, but cytoplasmic FUS-immunoreactive inclusions
were demonstrated in lower motor neurons of ALS patients
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type FUS was subsequently reported as the prominent disease
phenotype in other neurodegenerative diseases such as basophilic
inclusion body disease [20], some types of juvenile ALS [21], and
in the majority of tau- and TDP43-negative FTLD [22]. The
identification of these two RNA-binding proteins that aggregate
and are sometimes mutated in ALS and FTLD gave rise to the
emerging concept that disturbances in RNA regulation may play a
major role in the pathogenesis of ALS and FTLD [23]. Moreover,
FUS aggregation is also demonstrated in Huntington’s disease,
spinocerebellar ataxia types 1, 2, and 3, and dentatorubropallido-
luysian atrophy [24,25]. These findings suggest an important role
for FUS aggregation in the pathogenesis of neurodegenerative
diseases beyond ALS and FTLD.
FUS is a ubiquitously expressed, 526 amino acid protein that
was initially identified as a proto-oncogene, and which causes
liposarcoma due to chromosomal translocation [26]. FUS is an
RNA-binding protein that is implicated in multiple aspects of
RNA metabolism including microRNA processing, RNA splicing,
trafficking and translation [23,27,28]. FUS shows nuclear and
cytoplasmic expression and shuttles between the nucleus and the
cytoplasm [27,29]. In neurons, FUS is localized to the nucleus but
it is transported to dendritic spines at excitatory post-synapses in a
complex with RNA and other RNA-binding proteins [30]. Similar
to TDP-43, FUS comprises a glycine-rich domain (GRD), an
RNA-recognition-motif (RRM) domain and a nuclear localization
sequence (NLS). ALS/FTLD-associated mutations cluster in the
C-terminal region of the FUS protein that contains a non-classical
R/H/KX2–5PY NLS motif [31] as well as in the GRD motif that
is important for protein-protein interactions and also exists in the
C-terminal region of TDP-43. Most pathogenic mutations of the
TARDBP gene cluster in this GRD motif. The only known genetic
cause for ALS/FTLD with FUS pathology is mutations in the FUS
gene itself. The FUS mutations in the NLS-containing C-terminal
region lead to redistribution of the FUS protein from the nucleus
to the cytoplasm [32–35]. These findings suggest that the loss of
physiological nuclear functions of FUS that involve RNA
regulation may contribute to the pathogenesis of ALS/FTLD.
There is a single homolog for each of human FUS and TDP-43
in Drosophila, named Cabeza (Caz) and TBPH, respectively. The
Caz gene is located on the X chromosome, and is a member of an
RNA binding proteins that are conserved from fly to man. In situ
hybridization and immunohistochemical analyses demonstrated
that Caz mRNA and protein are enriched in the brain and CNS
during embryogenesis, and the Caz protein was detected in the
nuclei of several larval tissues and in imaginal discs [36]. The full-
length recombinant Caz protein and its RRM domain are capable
of binding RNA in vitro [36]. These findings suggest that Caz is a
nuclear RNA binding protein that may play an important role in
the regulation of RNA metabolism during fly development.
Feiguin et al. reported that Drosophila lacking TBPH presented
deficient locomotive behaviors, reduced life span and anatomical
defects at neuromuscular junctions (NMJ), suggesting that a loss of
TDP-43 nuclear functions could be a causative factor of the
neurodegeneration observed in patients with ALS/FTLD [37].
As mentioned above, the loss of the nuclear function of FUS or
TDP-43 plays an important role in the pathogenesis of ALS/
FTLD. However, aggregation of TDP-43 or FUS may by itself be
toxic due to a toxic gain-of-function associated with the formation
of cytoplasmic aggregates of those proteins, which would trap vital
proteins and/or RNAs and might disturb cellular homeostasis.
Thus, it remains unclear whether it is the loss of FUS nuclear
function or the gain of toxic function resulting from FUS
aggregation that is the mechanism that underlies the primary
abnormality that leads to the neurodegeneration that occurs in
ALS/FTLD. The existence of both dominantly and recessively
inherited FUS mutations in familial ALS has provoked further
controversy regarding whether the underlying pathogenic mech-
anism of ALS/FTLD is due to gain-of-toxic-function or loss-of-
nuclear function [15,19,38]. Here, we investigated phenotypes of
fly models with knockdown of the Drosophila FUS homologue, Caz
gene, to provide supporting evidence for our hypothesis that the
pathogenesis of ALS/FTLD may be due more to the loss of
physiological FUS functions than to the toxicity of its cytoplasmic
aggregates. Neuron-specific knockdown of the Drosophila Caz gene
reduced the climbing abilities of adult flies as well as caused
anatomical defects, such as a reduced length of synaptic branches,
in presynaptic terminals of motoneurons in third instar larvae,
suggesting that decreased expression of the Drosophila FUS
homologue may be sufficient for development of the degeneration
of motoneurons and for the deficient locomotive behavior in this
model fly.
Results
Comparison of the amino acid sequence of human FUS
and Drosophila Caz
The amino acid sequence of Drosophila Caz was retrieved from
the Flybase and was compared with that of human FUS using
BLAST and FASTA (Figure 1). The identity and the similarity of
the amino acid sequences of Caz and FUS are 44.9% and 62.3%,
respectively. Regarding conservation of specific FUS domains, the
RRM domain, which is known to bind RNAs, as well as the zinc
finger domain, are both highly conserved between human FUS
and Drosophila Caz, showing 50% and 63% identity, respectively.
The similarity of the human and Drosophila RRM and zinc finger
domains is as high as 75% and 73%, respectively.
Specificity of the anti-Caz antibody
We raised a polyclonal antibody against a mixed peptide
corresponding to residues 30–45 and 382–390 of Drosophila Caz for
immunological studies. In order to confirm the specificity of this
antibody, we used this anti-Caz polyclonal antibody for immuno-
blotting analyses of CNS extracts of third instar larvae carrying
elav
3A-GAL4/+ (elav
3A/+, a driver control fly), UAS-Caz-IR/+ (a
responder control fly), and RNAi transgenes encoding inverted
repeats corresponding to various Caz regions, elav
3A-GAL4.UAS-
Caz-IR (Figure 2). A single major band with an apparent molecular
weight of 45 kDa was detected on immunoblots of all of the flies
using the anti-Caz antibody (Figure 2A). Although the size of this
protein was slightly larger than the size (38.8 kDa) of the Caz
protein predicted based on its amino acid composition, the
intensity of this band was significantly reduced in flies carrying
elav
3A-GAL4.UAS-Caz-IR1-167 (elav
3A/Caz-IR1-167) and those car-
rying elav
3A-GAL4.UAS-Caz-IR363-399 (Caz-IR363-399/+;elav
3A/+)
compared with its intensity in either driver control flies (elav
3A/+)
or responder control flies (UAS-Caz-IR1-167/+) (Figure 2B). There
was a significant increase in Caz protein level in CNS extracts
from the flies carrying elav
3A/Caz-IR180-346 compared with those
from control flies carrying elav
3A/+ with unknown causes
(Figure 2B). These results indicate that the anti-Caz antibody
can specifically detect the Caz protein. These data also confirmed
that Caz is effectively knocked down in flies carrying elav
3A/Caz-
IR1-167 and Caz-IR363-399/+;elav
3A/+, but it is not knocked down in
flies carrying elav
3A-GAL4.UAS-Caz-IR180-346, which we did not
therefore use in the subsequent experiments.
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nervous system of Drosophila
The polyclonal anti-Caz antibody was used to examine the
expression pattern of the Caz protein in the CNS of third instar
Drosophila larvae and adult flies (Figure 3). Drosophila Caz was
strongly expressed in the CNS of both larvae (Figure 3, A1) and
adults (Figure 3, E1). No signal was generated in the absence of the
primary anti-Caz antibody (Figure 3, D, H) indicating that this
signal is specific for detection of the Caz protein. Moreover, the
anti-Caz antibody signal did not overlap with the signal of the
presynaptic marker Bruchpilot (Brp) that was detected using an
anti-Brp antibody (Figure 3, A3-A4, E3-E4). This finding indicates
that Caz localizes in a region other than synaptic areas both in
third instar larvae and in adult flies (Figure 3, A1-A4, E1-E4), and
Figure 1. Comparison of human FUS and Drosophila Caz. (A) Alignment of human FUS and Drosophila Caz amino acid sequences. Identity is
indicated in blue. The RNA-recognition-motif (RRM) domain is outlined with a red box. (B) Schematic drawings of domain structures of Human FUS
and Drosophila Caz proteins. The human FUS protein contains an N-terminal QGSY-rich domain, which functions as a potent transcriptional activation
domain [62–64]. The glycine-rich domain (G rich), RRM domain, a domain containing multiple Arg-Gly-Gly (RGG) motifs and a zinc finger (ZnF), are all
involved in RNA binding [65,66]. A solid line under the schema of Drosophila Caz shows the target genomic sequence of each of the three RNAi
transgenes employed in this study, UAS-Caz-IR1–167, UAS-Caz-IR180–346 and UAS-Caz-IR363-399.
doi:10.1371/journal.pone.0039483.g001
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cell bodies and/or their axons.
Regarding the precise localization of the Caz protein in
neuronal cell bodies, Caz immunoreactivity was detected in the
nucleus of neuronal cells of third instar larvae and did not co-
localize with actin filaments, which are cytosolic proteins (Figure 4).
However, within the nucleus, Caz did not co-localize with
diamino-2-phenylidole (DAPI), suggesting that Caz is not localized
on chromosomes but is localized in the nucleoplasm (Figure 4, C
and D).
Neuron-specific Caz knockdown causes fly mobility
defects
To analyze the effect of Caz knockdown on fly phenotypes, we
first investigated whether fly viability was affected by whole-body
knockdown of Caz. Using an Act5C-GAL4 driver that expresses
GAL4 in the whole body of the fly, we analyzed the phenotypes of
flies in which Caz double-stranded RNA was expressed throughout
the whole body (Table 1). When crossed at 28uC, UAS-Caz-IR1-167
was lethal at the pupal stage for all fly strains that carried it, while
the strains carrying UAS-Caz-IR180-346 were viable. When crossed
at 25uC to decrease the expression levels of Act5C-GAL4, almost all
of the strains carrying UAS-Caz-IR1-167, for which UAS-Caz-IR1-167
had been lethal when crossed at 28uC, changed to be viable.
We next established transgenic fly lines in which Caz double-
stranded RNA was specifically expressed in neuronal tissue by
crossing the transgenic flies with the elav
3A-GAL4 line. As shown
above in the immunoblotting analyses of the fly CNS (Figure 2),
the expression levels of the Caz protein were much decreased in
strain 3 of the fly lines that carried elav
3A/Caz-IR1-167 and in the fly
line carrying Caz-IR363-399/+;elav
3A/+, compared with the control
flies. However, Caz expression levels did not show any detectable
decreases in the fly lines carrying elav
3A-GAL4.UAS-Caz-IR180-346.
Similar to these results of immunoblotting analyses, immunostain-
ing of the CNS of third instar larvae (Figure 3, B1, C1) and adult
flies (Figure 3, F1, G1) showed that immunoreactivity detected
with the anti-Caz antibody also decreased in the CNS tissues
derived from the fly lines carrying elav
3A/Caz-IR1-167 (strain 3)
(Figure 3, B1: larva, F1: adult fly) and Caz-IR363-399/+;elav
3A/+
(Figure 3, C1: larva, G1: adult fly). These results confirmed that
Caz is effectively knocked down in the CNS of those two lines of
transgenic flies.
To examine the effects of neuron-specific Caz-knockdown on
the fly life span, we next determined the life span of each genotype
(Figure 5). We examined adult flies until 120 days after eclosion,
but there were no significant differences in life span between the
control flies carrying elav
3A/+ (n=145) and those carrying elav
3A/
Caz-IR1-167 (n=144) or Caz-IR363-399/+;elav
3A/+ (n=161), in
which the CNS expression of Caz was efficiently knocked down
(Figure 5). The average life span of the control flies was 73.9 days,
whereas flies carrying elav
3A/Caz-IR1-167 and Caz-IR363-399/
+;elav
3A/+ lived an average of 76.5 days and 70.7 days, respec-
tively. Fly life spans were therefore not significantly different
between the control and neuron-specific Caz-knockdown flies.
In order to further evaluate the functional effects of neuron-
specific Caz knockdown, we then performed climbing assays of the
Caz-knockdown fly strains (Figure 6). The flies carrying elav
3A/Caz-
IR1-167 showed reduced mobility both on day 3 (210.7%) and day
21 (29.3%) compared to the control flies carrying elav
3A/+.
Similarly Caz-IR363-399/+;elav
3A/+ carrying flies showed reduced
mobility both on day 3 (25.1%) and on day 21 (210.6%). All of
these reductions in mobility were statistically significant (p,0.001).
These results indicate that Caz is involved in locomotion.
Figure 2. Western immunoblot analysis of the CNS extracts of
third instar larvae. (A) A representative result of the analysis of
protein extracts from the CNS of the driver control (elav
3A/+) and
responder control (UAS-Caz-IR180-346/+ and UAS-Caz-IR1-167/+) flies (n=5,
each) and transgenic flies (elav
3A/Caz-IR180-346, Caz-IR363-399/+;elav
3A/+
and elav
3A/Caz-IR1-167) (n=5, each). The blots were probed with the
polyclonal anti-Caz antibody that was newly raised for this study. a-
Tubulin was used as a loading control. A 45-kDa band (arrow)
corresponds to the Caz protein. (B) Densitometric quantification of
the 45-kDa bands derived from triplicated immunoblot analyses of the
CNS tissues of each fly strain in (A). The intensity of the 45 kDa band
which indicates the expression level of Caz protein was much weaker in
flies carrying elav
3A/Caz-IR1-167 or Caz-IR363-399/+;elav
3A/+ than in the
driver and responder control flies. The columns and horizontal bars
indicate the mean values and the standard errors of the triplicated
experiments. **p,0.01 (vs. elav
3A/+), *** p,0.001 (vs. elav
3A/+),
##p,0.01 (vs. UAS-Caz-IR1-167/+),
###p,0.001 (vs. UAS-Caz-IR1-167/+).
doi:10.1371/journal.pone.0039483.g002
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presynaptic terminals in the NMJ
Based on the fact that Caz-knockdown flies showed motor
deficits in the climbing assays, together with the fact that FUS, the
human counterpart of Caz, is involved in ALS that impairs motor
neurons, we therefore decided to analyze the morphology of
motoneuron presynaptic terminals at NMJs in these flies. Because
most motoneurons of the adult fly originate from larval
motoneurons, we compared the NMJ structure of the larvae of
elav
3A/Caz-IR1-167 and Caz-IR363-399/+;elav
3A/+ flies with that of
larvae of control flies carrying elav
3A/+ or UAS-Caz-IR363-399/+.
None of these Caz-knockdown fly larvae showed apparent changes
in NMJ structure (Figure 7, A-D). However, measurement of the
total length of synaptic branches of motoneurons in these larvae
indicated that the total branch length was significantly decreased
in elav
3A/Caz-IR1-167 (75.3611.9 mm) and Caz-IR363-399/+;elav
3A/+
(75.3619.5 mm) flies compared to that of the both driver (elav
3A/+;
94.8619.9 mm) and responder (UAS-Caz-IR363-399/+;
105.4617.5 mm) control flies. (Figure 7, E). The flies carrying
elav
3A/Caz-IR1-167 showed the significantly decreased number of
the synaptic boutons (9.362.1) compared to the both driver
(15.964.5) and responder (17.164.7) control flies, and so did the
flies carrying Caz-IR363-399/+;elav
3A/+ (11.865.6) compared to the
responder controls (Figure 7, F). There were no significant
differences in the size of synaptic boutons among those 4
genotypes (Figure 7, G). These results indicate that Caz is
required for synaptic terminal growth at the NMJ.
Discussion
We showed here that Drosophila Caz is strongly expressed in the
central nervous system of larvae and adults. Caz did not colocalize
with the presynaptic protein Brp, suggesting that Caz performs its
physiological functions in neuronal cell bodies and/or their axons.
In order to clarify whether or not disruption of the physiological
functions of Caz are critical for the development of neurodegen-
eration even in the absence of abnormal Caz aggregates, we
established fly models in which the Caz gene, which is the
Drosophila FUS homologue, was knocked down. We demonstrated
that neuron-specific knockdown of Caz did not affect the life span
of the Caz-knockdown flies but did reduce the climbing abilities of
adult flies, and also caused anatomical defects in presynaptic
terminals of motoneurons in third instar larvae. These results
suggested that a decrease in Caz expression is sufficient for the
development of defects in locomotive abilities and for a decrease in
the total length of synaptic branches of motoneurons at the NMJs
in this Drosophila model. These data may indicate that the loss of
physiological FUS functions in motoneurons would be more
fundamental than the formation of cytoplasmic FUS aggregates in
the pathogenesis of human FUS-related ALS/FTLD.
To eliminate the possibility that off-target effects of our RNAi
construct that contained inverted repeats might generate the
observed phenotypes, we used two different Caz inverted repeat
constructs (UAS-Caz-IR1-167 and UAS-Caz-IR363-399) whose target
sequences did not overlap with each other. We established four
transgenic fly strains carrying UAS-Caz-IR1-167 as listed in Table 1.
We also obtained a fly strain carrying UAS-Caz-IR363-399 from the
Vienna Drosophila RNAi center (VDRC). This fly strain carries an
RNAi that is targeted to the region corresponding to residues 363-
399 of Drosophila Caz (UAS-Caz-IR363-399), We then crossed these
transgenic flies with the elav
3A-GAL4 line to specifically express Caz
double stranded RNA in neuronal tissues. Each independent fly
strain carrying elav
3A/Caz-IR1-167 showed essentially the same
phenotype as the strain carrying Caz-IR363-399/+;elav
3A/+. These
results suggest that the phenotypes observed in the neuron-specific
Caz-knockdown flies were not due to an off-target effect but rather
to a reduction in Caz protein levels.
Mutations in the FUS gene are associated with inherited forms
of both ALS and FTLD [15,16,18,19]. The FUS gene was
originally identified in a study that found that the FUS protein
forms part of a fusion protein with the transcription factor CHOP,
which arises due to a chromosomal translocation in liposarcoma
[26]. It has been reported that there are both dominantly and
recessively inherited families of ALS with FUS mutations [15].
Before the discovery of these FUS mutations in familial ALS,
mutations in the TARDBP gene that encodes another RNA-
binding protein, TDP-43, had been reported to be associated with
familial ALS and FTLD [7-14]. Both the FUS gene and the
TARDBP gene encode an RNA-binding protein equipped with an
RRM, and should therefore be involved in RNA processing,
splicing, and RNA metabolism. Since FUS and TDP-43 have
substantial similarities in their protein structure and putative
functions, they could therefore cause ALS or FTLD through
common pathogenic processes [2,38]. However, the mechanisms
through which mutations in FUS or TARDBP cause ALS and
FTLD are not known, and both toxic gain-of-function and loss-of-
function models have been proposed [2,38]. ALS-associated
mutant forms of TDP-43 and FUS are known to form abnormal
cytosolic aggregates [15,16,35,39–41], and high-level overexpres-
sion of either wild-type or mutant TDP-43 is neurotoxic in mice,
zebra fish and Drosophila [42–47]. One recent study reported that a
Drosophila model in which targeted expression of mutant human
FUS in Drosophila motor neurons led to locomotor dysfunction
[48]. These findings would support the toxic gain-of-function
model. However, overexpression of mutant proteins may also
perturb the activity of endogenous TDP-43, supporting the loss-of-
function model [49]. Similarly, the targeted expression model
mentioned above reported that deletion of the nuclear export
signal rescued toxicity associated with mutant FUS, suggesting that
delocalization of FUS from the nucleus to the cytoplasm, namely
the loss-of-nuclear-function, would be necessary for neurodegen-
eration [48]. In this study, we demonstrated that neuron-specific
knockdown of Caz, the Drosophila FUS homologue, could induce a
defect in fly locomotive abilities as well as degeneration of
motoneurons at NMJs in the model flies. There has been one
previous report that showed that flies lacking TBPH, the Drosophila
TDP-43 homologue, present deficient locomotive behaviors,
reduced life span and anatomical defects at the NMJs [37].
Regarding FUS and its homologues, one recent study reported that
Drosophila mutants in which the Caz gene was disrupted exhibited
Figure 3. Immunohistochemical localization of Caz in larval and adult brains. Brain-ventral ganglia complexes from third instar larvae (A–D)
and whole mount adult heads (E–H) were stained with the polyclonal anti-Caz antibody (A-1, B-1, C-1, E-1, F-1, G-1) or with an antibody against the
neuropil marker Bruchpilot (Brp) (A-2, B-2, C-2, E-2, F-2, G-2). Merged confocal images of the two stains are shown at right (A-3, B-3, C-3, E-3, F-3 and
G-3, respectively). Higher-magnification images of the boxed area in A-3 and E-3 are shown in A-4 and E-4, respectively. (D, H) Images of staining in
the absence of first antibody. A-1 to A-4, E-1 to E-4, controls carrying elav
3A/+; B-1 to B-3, F-1 to F-3, Caz-knockdown flies carrying elav
3A/Caz-IR1-167;C -
1 to C-3, G-1 to G-3, Caz-knockdown flies carrying Caz-IR363-399/+;elav
3A/+. Caz antibody immunoreactivity decreased in CNS tissues from both the
third instar larvae and the adult flies carrying elav
3A/Caz-IR1-167 (B-1, F-1) and Caz-IR363-399/+;elav
3A/+ (C-1, G-1). The single bars indicate 100 mm. The
double bars indicate 20 mm.
doi:10.1371/journal.pone.0039483.g003
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39483Figure 4. Intraneuronal localization of Caz in larval brains. Brain-ventral ganglia complexes from third instar larvae (A–D) were stained with
the anti-Caz antibody (A-1, B-1), diamino-2-phenylidole (DAPI) (nuclear staining; A-2, B-2) or phalloidin (F-actin staining; A-3, B-3). Panels B-1 to B-4 are
higher magnification images of the boxed area in A-1. Merged confocal images of A-1 to A-3, B-1 to B-3, B-1 and B-2, and B-1 and B-3 are shown in A-
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life span compared with controls, and that these phenotypes were
fully rescued by wild-type human FUS, but not by ALS-associated
mutant FUS [50]. These reports, together with our results,
demonstrated that a lack of physiological functions of FUS or
TDP-43 in the nucleus is sufficient for induction of locomotive
dysfunction and motoneuron degeneration, which recapitulate the
phenotypes of ALS, and they therefore imply that the loss of
physiological FUS functions are sufficient for the development of
pathogenic processes similar to those that occur in FUS- or TDP-
43-related ALS/FTLD, in the absence of cytosolic aggregates that
may be toxic to motoneurons in ALS/FTLD.
There have been a few previous studies in which loss-of-function
animal models of FUS-related human disorders were generated.
FUS knockout mice show perinatal lethality and defects in B
lymphocyte development [51]. Additionally, the hippocampal
pyramidal neurons of these FUS-null mice exhibited abnormal
spine morphology and lower spine density [52]. One report
showed that surviving knockout mice exhibited male sterility [53].
However, the neurodegenerative phenotypes of these mice have
not been reported to date. With regard to Drosophila models, one
recent paper that was mentioned above presented a mutant fly
strain (named the Caz1 mutant) in which 58% of the Caz gene was
deleted by creating a small genomic deletion [50]. This fly model
developed a phenotype of disturbed locomotion that is similar to
that observed in the Caz-knockdown flies in the present study. The
differences between the Caz1 mutant and our fly models were as
follows; 1) the Caz1 mutant did not show any morphological
abnormalities at the NMJs i.e., shortening of the presynaptic
terminals of motoneurons and decrease in the number of synaptic
boutons, both of which were observed in our Caz-knockdown
models. 2) The Caz1 mutant showed reduced life spans, which
were not observed in our models, and this life-span defect of Caz1
mutant could be fully rescued by expression of wild-type fly Caz or
wild-type human FUS in neurons using elav-Gal4. The difference in
life span between the Caz1 mutant and our Caz-knockdown
models might be caused by differences in the expression pattern of
the transgenes between the two models; in our fly models Caz gene
expression was knocked down specifically in the nervous system,
whereas, in the short-lived Caz1 mutant flies, Caz was disrupted
throughout the whole body. In our Caz-knockdown models, the
expression of Caz protein was knocked down to 40–60% in the
CNS (Figure 2), but their life spans were not reduced. Together
with the fact that the reduced life span of the Caz1 mutant was
rescued by the neuronal expression of wild-type Caz, our results
suggest that substantial expression of Caz in neuronal tissues, even
though it is not fully expressed, could sufficiently keep their life
spans within normal range. Our model flies also demonstrated that
normal expression of Caz in neurons is essential for the elongation
of synaptic branches of motoneurons at NMJs, and therefore that
Caz-knockdown would induce impaired maturation of these
synaptic branches, resulting in the observed locomotive deficit in
our model flies, in the absence of any non-neuronal effect of the
Caz protein.
In conclusion, we established fly models with neuron-specific
knockdown of the Drosophila FUS homologue, and showed that
those flies developed locomotive deficits as well as anatomical
defects of motoneurons at NMJs. Our results indicate that the loss
4, B-4, C, and D, respectively. The bar indicates 100 mm (A) or 5 mm (B–D). Anti-Caz antibody-immunoreactivity was detected in the nucleus of
neuronal cells and did not co-localize with actin filaments, which stained with phalloidin. Since Caz did not co-localize with DAPI, which stains
chromosomes, Caz must therefore localize in the nucleoplasm.
doi:10.1371/journal.pone.0039483.g004
Table 1. Established fly strains carrying UAS-Caz-IR.
Transgene Strain
Chromosome
linkage Act5C-GAL4.
elav
3A-
GAL4.
286C2 5 6C
UAS-Caz-
IR1-167
3 III lethal lethal LD (+)
4 III lethal NE ND
11 II lethal NE ND
21 III lethal NE ND
UAS-Caz-
IR180-346
11 II NE NE NE
12 II NE NE NE
17 II NE NE ND
22 III NE ND LD (2)
24 III NE NE LD (2)
32 III ND ND ND
33 III ND NE ND
UAS-Caz-IR363-399 II NE ND LD (+)
LD: locomotive dysfunction, NE: no effect, ND: not determined.
doi:10.1371/journal.pone.0039483.t001
Figure 5. Life-span analyses of flies of each genotype.
Percentage survival of adult male flies of the indicated genotypes is
shown. Flies were collected from 20 different batches. The total number
of flies counted was: elav
3A/+ (n=145), elav
3A/Caz-IR1-167 (n=144) and
Caz-IR363-399/+;elav
3A/+ (n=161). There were no significant differences in
the life span of flies with the indicated genotypes.
doi:10.1371/journal.pone.0039483.g005
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the fundamental pathogenic mechanism that causes FUS-related
ALS/FTLD than the toxicity of cytoplasmic aggregates. These
data further indicate future research directions, suggesting that it
will be necessary to identify target molecules, including nuclear
proteins and/or RNA species that associate with FUS, in order to
elucidate the molecular mechanisms leading to neuronal dysfunc-
tion in FUS-associated ALS/FTLD and to develop the disease-
modifying therapies that are eagerly desired in those relentless
neurodegenerative diseases. In any event, the Drosophila model that
we established in the present study, which recapitulates key
features of human ALS, would be suitable for the screening of
genes and chemicals that can modify these pathogenic processes
that lead to the degeneration of motoneurons in ALS.
Materials and Methods
Fly stocks
Fly stocks were maintained at 25uC on standard food containing
0.7% agar, 5% glucose and 7% dry yeast. Canton S was used as
the wild type. W; UAS-Caz-IR; + (CG3606) was obtained from the
Vienna Drosophila RNAi center (VDRC). The RNAi of this strain
was targeted to the region corresponding to residues 363-399 of
Drosophila Caz (UAS-Caz-IR363-399). P{GAL4-elav.L}3A (elav
3A-
GAL4) was provided by Dr. Bryan Stewart [54]. The Act5C-
GAL4 strain was obtained from the Bloomington Drosophila stock
center. Establishment of the lines carrying GMR-GAL4 was as
described previously [55].
Comparison of amino acid sequences of human FUS and
Drosophila Caz
The amino acid sequence of Drosophila Caz was retrieved from
the Flybase (http://flybase.org). The identity and the similarity of
Drosophila Caz and human FUS were compared using BLAST
(http://blast.genome.jp/) and FASTA (http://fasta.genome.jp/).
FASTA was used for comparison of the entire sequences, and
BLAST was used for comparison of each corresponding domain
between Caz and FUS.
Establishment of the transgenic flies
To establish transgenic fly lines carrying UAS-Caz-IR, 500-bp
fragments of Caz ORFs (UAS-Caz-IR1-167;5 9-ATGGAAC-
GTGGCGGTTATGGTGGT to 59-AGAACAAGGAGACCG-
GCGC, UAS-Caz-IR180-346;5 9-ATGCTGCACAATCCGCCAT-
TGAAT to 59-CAACAGAGATCGCGGTGGC) from Caz cDNA
clone CG3606 were amplified, and then individually cloned into
the pENTR/D-TOPO vector (Invitrogen Life Technologies Japan
Corporation, Tokyo, Japan), in which each trigger sequence of Caz
was placed between the attL1 and attL2 recombination sequences.
Following confirmation by sequencing, two copies of each trigger
sequence were transferred into the pRISE transformation vector
that contains a characteristic inverted repeat of attR1-cm
r-ccdB-
attR2 in a recombination cassette by an in vitro reaction mediated
by LR Clonase (Invitrogen), a DNA recombinase that specifically
recognizes the attL and attR2 target sites [56]. Due to the
recombination reaction between the attL and attR2 sites, the ccdB
sequence was replaced by the target cDNA, resulting in the
cloning of a head-to-head inverted repeat (IR) of Caz into the
plasmid.
These plasmids were verified by sequencing and then injected
into embryos to obtain stable transformant lines carrying UAS-
Caz-IR. P element-mediated germ line transformation was carried
out as described previously [57], and F1 transformants were
selected on the basis of white-eye color rescue [58]. Four and seven
transgenic strains carrying UAS-Caz-IR1-167 and UAS-Caz-IR180-346
were established, respectively (responder controls), as listed in
Table 1. To drive expression of Caz double stranded RNA in the
whole body of the flies or specifically in neuronal tissues, we
crossed the transgenic flies with either the Act5C-GAL4 line or the
elav
3A-GAL4 line (elav
3A-GAL4/+; a driver control). Each transgenic
strain showed a consistent phenotype (Table 1).
Production of rabbit anti-Caz antibodies
Rabbit anti-Caz antibodies were produced by MEDICAL &
BIOLOGICAL LABORATORIES Co., Ltd (MBL, Ina, Japan).
The peptides, N-NKTGNYEPPPNYGKQGC-C (residues 29–45;
the underlined C residue C was an added residue) and N-
CRDGGPMRNDGGMRSRPY-C (residues 383–399), which
correspond respectively to the N- and C-terminal sequences of
Caz, were individually conjugated with KLH (Keyhole limpet
hemocyanin). These two KLH-conjugated peptides were mixed
with Freund’s complete adjuvant to provide a suspension, which
was injected intradermally into rabbits (Female Japanese White).
The rabbits were then boosted with inoculations of an immunogen
of the same quality once a week for 7 weeks, and a terminal bleed
was performed to collect the maximum amount of serum. The
serum was purified by affinity chromatography against the
synthesized peptides using a Protein G column.
Figure 6. Climbing assays. Five independent tests were performed
for each genotype. The total number of flies counted was: elav
3A/+ (a
driver control, n=309), UAS-Caz-IR363-399/+ (a responder control,
n=222), UAS-Caz-IR1-167/+ (a responder control, n=246), Caz-IR363-399/
+;elav
3A/+ (n=265) and elav
3A/Caz-IR1-167 (n=238). There was no
significant difference in climbing abilities between the driver and
responder control flies in each day after eclosion. Flies carrying elav
3A/
Caz-IR1-167 or Caz-IR363-399/+;elav
3A/+ showed a significantly reduced
ability to climb upwards compared to elav
3A/+ flies in each examined
day. The horizontal bars indicate standard errors of mean values.
***p,0.001, **p,0.005.
doi:10.1371/journal.pone.0039483.g006
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e39483Figure 7. Confocal images of anti-HRP staining of muscle 4 synapses in third instar larvae. A representative image of the indicated
genotypes is shown; (A) elav
3A/+ (a driver control), (B) UAS-Caz-IR363-399/+ (a responder control), (C) elav
3A/Caz-IR1-167 and (D) Caz-IR363-399/+;elav
3A/+.
The bar indicates 20 mm. (E) Total branch length of the NMJ from muscle 4 for each of the indicated genotypes. n=9 for each genotype. (F, G) The
number (F) and the size (G) of the synaptic boutons for each of the indicated genotypes. (F) n=9 for each genotype. (G) The size of Ib bouton
(indicated with an arrow in A) was measured. n=30 for elav
3A/+, n=34 for Caz-IR363-399/+, n=27 for elav
3A/Caz-IR1-167, n=34 for Caz-IR363-399/+elav
3A/
+. The Caz-knockdown flies did not show any apparent changes in NMJ structure. However, the total length of synaptic branches of the motoneurons
was significantly decreased in each Caz-knockdown fly strain (elav
3A/Caz-IR1-167 and Caz-IR363-399/+;elav
3A/+) compared to the both driver and
responder control flies (E). The flies carrying elav
3A/Caz-IR1-167 showed the significantly decreased number of the synaptic boutons compared to the
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Protein extracts from the central nervous system (CNS) of
Drosophila carrying elav
3A-GAL4/+, UAS-Caz-IR180-346/+, UAS-Caz-
IR1-167/+ and elav
3A-GAL4.UAS-Caz-IR were prepared as previ-
ously described [59]. Briefly, the CNS was excised from third
instar larvae and homogenized in a sample buffer containing
50 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 0.1%
bromophenol blue and 1.2% b-mercaptoethanol. The homoge-
nates were boiled at 100uC for 5 min, and then centrifuged. The
supernatants (extracts) were electrophoretically separated on SDS-
polyacrylamide gels containing 12% acrylamide and then trans-
ferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad,
Osaka, Japan). The blotted membranes were blocked with TBS/
0.05% Tween containing 5% skim milk for 1 h at 25uC, followed
by incubation with rabbit polyclonal anti-Caz at a 1:5,000 dilution
for 16 h at 4uC. After washing, the membranes were incubated
with HRP-conjugated anti-rabbit IgG (GE Healthcare Bioscience,
Tokyo, Japan) at 1:10,000 dilution for 2 h at 25uC. Antibody
binding was detected using ECL Western blotting detection
reagents (GE Healthcare Bioscience) and images were analyzed
using a Lumivision Pro HSII image analyzer (Aisin Seiki, Kariya,
Japan). To ensure equal protein loading in each lane, the
membranes were also probed with an anti-a-tubulin antibody
after stripping the complex of anti-Caz antibody and HRP-
conjugated anti-rabbit IgG. For the detection of a-tubulin, mouse
anti-a-tubulin monoclonal antibody (1:5,000 dilution, Sigma,
Tokyo, Japan) and an HRP-conjugated anti-mouse IgG
(1:10,000 dilution, GE Healthcare Bioscience) were used as the
primary and secondary antibodies, respectively.
Immunostaining
For immunohistochemical analysis, CNS tissues of third instar
larvae and adult flies were dissected, and fixed in 4% parafor-
maldehyde/PBS for 15 min at 25uC. After washing with PBS
containing 0.3% Triton X-100, the samples were blocked with
blocking buffer (PBS containing 0.15% Triton X-100 and 10%
normal goat serum) for 30 min at 25uC, and then incubated with
diluted primary antibodies in the blocking buffer for 20 h at 4uC.
The following antibodies were used; 1:1,000 diluted rabbit anti-
Caz antibody and 1:100 diluted mouse anti-Brp antibody
(Developmental Studies Hybridoma Bank [DSBH] nc82). After
extensive washing with PBS containing 0.3% Triton X-100,
samples were incubated with secondary antibodies labeled with
either Alexa 546 or Alexa 488 (1:400; Invitrogen) diluted in the
blocking buffer, in the dark, for 2 h at 25uC. After extensive
washing with PBS containing 0.3% Triton X-100 and PBS,
samples were mounted in Fluoroguard Antifade Reagent (Bio-
Rad) and observed under a Zeiss LSM510 confocal laser scanning
microscope.
For NMJ staining, third instar larvae were dissected in HL3
saline [60] and fixed in 4% paraformaldehyde/PBS for 30 min.
The blocking buffer was 2% bovine serum albumin (BSA)/PBS/
0.1% TritonX-100. FITC-conjugated goat anti-HRP (1:1,000,
MP Biochemicals) was used as the detection antibody. The
samples were mounted and observed under a Zeiss LSM510
confocal laser scanning microscope. MN4 (Ib) in muscle 4 in
abdominal segment 2 was quantified. Images were acquired using
a Zeiss LSM510 by merging 1 mm interval z-sections onto a single
plane. Nerve terminal branch lengths were measured using Image
J software.
To determine whether Caz is present in the nucleus or not,
CNS tissues of third instar larvae were dissected, and fixed in 4%
paraformaldehyde/PBS for 15 min at 25uC. After washing with
PBS containing 0.3% Triton X-100, the samples were incubated
with Alexa 488-conjugated phalloidin (1 unit/200 ml) in PBS
containing 0.3% Triton X-100 for 20 min at 25uC. The samples
were then blocked and reacted with the primary and the
secondary antibodies as described for the immunohistochemical
analysis described above, except that the mouse anti-Brp antibody
was not used. After extensive washing with PBS containing 0.3%
Triton X-100, the samples were stained with DAPI (0.5 mg/ml)/
PBS/0.1% Triton X-100. Following washing with PBS containing
0.1% Triton X-100 and PBS, the samples were mounted and
observed under a confocal laser scanning microscope (OLYMPUS
Fluoview FV10i).
Longevity assay
Longevity assays were carried out in a humidified, temperature
controlled incubator at 25uC and 60% humidity on a 12-h light
and 12-h dark cycle on standard fly food. Flies carrying elav
3A-
GAL4/+ and elav
3A-GAL4.UAS-Caz-IR were placed at 28uC, and
newly eclosed adult flies were separated and placed in vials at a
low density (10–20 flies per vial) with a male: female ratio of 1: 1.
Every 3 days, they were transferred to new tubes containing fresh
food and deaths were scored. Survival rate was determined by
plotting a graph of the percentage of surviving flies versus days.
Climbing assay
Climbing assays were performed as described previously [61].
Flies carrying elav
3A-GAL4/+, UAS-Caz-IR363-399/+, UAS-Caz-IR1-
167/+, and elav
3A-GAL4.UAS-Caz-IR were placed at 28uC, and
newly eclosed adult flies were separated and placed in vials at a
density of 30 flies per vial (15 males and 15 females). Flies were
transferred, without anesthesia, to a conical tube. The tube was
tapped to collect the flies to the bottom, and they were then given
30 s to climb the wall. After 30 s the flies were collected at the
bottom by tapping of the tube, and were again allowed to climb for
30 s. Similar procedures, all of which were videotaped, were
repeated five times in total. For all of the climbing experiments,
the height to which each fly climbed was scored as follows (score
(height climbed)); 0 (less than 2 cm), 1 (between 2 and 3.9 cm), 2
(between 4 and 5.9 cm), 3 (between 6 and 7.9 cm), 4 (between 8
and 9.9 cm) and 5 (greater than 10 cm). The climbing index of
each fly strain was calculated as follows; the sum of the products of
each score multiplied by the number of flies for which that score
was recorded, was calculated, and this number was then divided
by five times the total number of flies examined. These climbing
assays were carried out every 3 days until the 18th day after
eclosion.
Data analysis
All statistical analyses were performed using Microsoft Excel.
The Mann-Whiney test was used for assessment of the statistical
significance of comparisons between groups of data concerning
median life span. For other assays the two-way ANOVA was used
to determine the statistical significance of comparisons between
groups of data. When the two-way ANOVA showed significant
both driver and responder control flies, and so did the flies carrying Caz-IR363-399/+;elav
3A/+ compared to the responder controls (F). There were no
significant differences in the size of synaptic boutons among those 4 genotypes (G). The horizontal bars indicate standard errors of mean values.
*p,0.05, **p,0.01.
doi:10.1371/journal.pone.0039483.g007
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for pairwise comparisons of groups. All data are shown as means
6 SEM.
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